Aquestive Therapeutics, Inc. financial data

Symbol
AQST on Nasdaq
Industry
Pharmaceutical Preparations
Location
30 Technology Drive, Warren, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
MonoSol Rx, Inc. (to 3/27/2008)
Latest financial report
10-K - Q4 2024 - Mar 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 610 % +343%
Quick Ratio 42.1 % +90.8%
Debt-to-equity -359 % -131%
Return On Equity 99.5 % +1245%
Return On Assets -38.5 % -188%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 98.9M shares +34.9%
Common Stock, Shares, Outstanding 91.4M shares +33.4%
Entity Public Float 207M USD +151%
Common Stock, Value, Issued 91K USD +31.9%
Weighted Average Number of Shares Outstanding, Basic 86.7M shares +41.6%
Weighted Average Number of Shares Outstanding, Diluted 86.7M shares +41.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 57.6M USD +13.8%
Research and Development Expense 20.3M USD +54.8%
Costs and Expenses 88.3M USD +34.5%
Operating Income (Loss) -30.8M USD -104%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.2M USD -479%
Income Tax Expense (Benefit) -14K USD -106%
Net Income (Loss) Attributable to Parent -44.1M USD -461%
Earnings Per Share, Basic -0.51 USD/shares -292%
Earnings Per Share, Diluted -0.51 USD/shares -292%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.9M USD +213%
Inventory, Net 6.04M USD -10.7%
Assets, Current 88.2M USD +115%
Property, Plant and Equipment, Net 3.8M USD -9.09%
Operating Lease, Right-of-Use Asset 5.18M USD -6.75%
Other Assets, Noncurrent 4.22M USD -22.3%
Assets 101M USD +76.6%
Accounts Payable, Current 10.3M USD +15.2%
Employee-related Liabilities, Current 4.73M USD +12.6%
Accrued Liabilities, Current 5.91M USD -9.08%
Contract with Customer, Liability, Current 1.05M USD -32.4%
Liabilities, Current 18.9M USD +3.04%
Long-term Debt and Lease Obligation 32.5M USD +18.1%
Contract with Customer, Liability, Noncurrent 20M USD -38.2%
Operating Lease, Liability, Noncurrent 4.97M USD -7.98%
Other Liabilities, Noncurrent 2.4M USD +18.8%
Liabilities 162M USD -1.42%
Retained Earnings (Accumulated Deficit) -363M USD -13.8%
Stockholders' Equity Attributable to Parent -60.2M USD +43.5%
Liabilities and Equity 101M USD +76.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD -218%
Net Cash Provided by (Used in) Financing Activities 81.7M USD
Net Cash Provided by (Used in) Investing Activities -29K USD -1350%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 91.4M shares +33.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 71.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 71.5M USD +200%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1M USD -31.6%
Deferred Tax Assets, Valuation Allowance 94.6M USD +12.5%
Deferred Tax Assets, Gross 95.3M USD +12.6%
Operating Lease, Liability 5.48M USD -5.68%
Depreciation 640K USD -44.5%
Payments to Acquire Property, Plant, and Equipment 29K USD +1350%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -44.1M USD -461%
Lessee, Operating Lease, Liability, to be Paid 9.04M USD -10.6%
Property, Plant and Equipment, Gross 47.3M USD +0.5%
Operating Lease, Liability, Current 510K USD +30.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.32M USD +4.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.28M USD +4.39%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.57M USD -17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.35M USD +3.54%
Deferred Tax Assets, Operating Loss Carryforwards 34.7M USD +27.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.18M USD -11.1%
Additional Paid in Capital 303M USD +42.6%
Amortization of Intangible Assets 78K USD -50.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 7.1M USD +164%
Interest Expense 9.09M USD +48.9%